DDInter1840 DDInter1733
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Trabectedin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Trabectedin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Trabectedin {u} (Compound) causes {v} (Side Effect) Pulmonary embolism
Pulmonary embolism {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Suvorexant
Trabectedin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Trabectedin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Trabectedin (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant